HCA-7 Colony 29

2091238, human colon, Epithelial

• UNSPSCコード: 41106514

特性

• 製品名: HCA-7 Colony 29, NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA., 02091238
• 由来生物: human colon
• 包装: tube of 5 μg 02091238-DNA-5UG; pkg of vial of cells 02091238-1VL
• 成長モード: Adherent
• 核型: Near Diploid
• 形態: Epithelial
• 製品: Expresses Cox-2
• 受容体: EGF. Parent HCA-7 cell line: wildtype APC. Known mutations:Parent HCA-7 cell line: RER phenotype, p53
• テクニック: cell culture | mammalian: suitable
• 関連疾患: cancer
• 輸送温度: dry ice
• 保管温度: −196°C

詳細

細胞株の由来

Human Colon Carcinoma (subpopulation isolated from the HCA-7 cell line)

細胞株の説明

The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations.

DNAプロファイル

STR-PCR Data: Amelogenin: X
CSF1PO: 11,14
D13S317: 9
D16S539: 10,11
D5S818: 8,12
D7S820: 11,12
THO1: 6,7
TPOX: 8,10
vWA: 14,16

培地

DMEM + 10% FBS + 2mM L-Glutamine + 110mg/L Sodium Pyruvate (NaP).

継代と培養方法

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C.

その他情報

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

免責事項

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.